Patents by Inventor Mark L. Wolfe

Mark L. Wolfe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for measuring ion channel conductance
    Publication number: 20040132187
    Abstract: The invention relates ton novel methods for measuring ion channel transmission and methods and compositions useful in the indentification of ligand gated channel agonists and modulators.
    Type: Application
    Filed: December 18, 2003
    Publication date: July 8, 2004
    Inventors: Vincent E. Groppi, Mark L. Wolfe, Mitchell B. Berkenpas
  • Double mutant alpha-7 nicotinic acetylcholine receptor
    Patent number: 6693172
    Abstract: The invention relates to a novel methods for measuring cellular ion channel transmission and methods and compositions useful in the identification of ligand gated ion channel agonists and modulators.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: February 17, 2004
    Assignee: Pharmacia and Upjohn Company
    Inventors: Vincent E. Groppi, Jr., Mark L. Wolfe, Mitchell B. Berkenpas
  • Protein affecting K.sub.ATP channels
    Patent number: 5925742
    Abstract: This invention describes the isolation and identification of a new protein, p56, useful for the identification of drugs that will selectively open or close K channels. The protein p56 has a molecular weight of about 56,000 daltons and the N-terminal peptide sequence is: Glu-Pro-Arg-Ala-Pro-Pro-Glu-Lys-Ile-Ala-Ile-Val-Gly-Ala-Gly-Ile.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: July 20, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Vincent E. Groppi, Jr., Martin R. Deibel, Jr., Mark L. Wolfe, Anthony W. Yem
  • Protein affecting K.sub.ATP channels
    Patent number: 5856449
    Abstract: This invention describes the isolation and identification of a new protein, p56, useful for the identification of drugs that will selectively open or close K channels. The protein p56 has a molecular weight of about 56,000 daltons and the N-terminal peptide sequence is: Glu-Pro-Arg-Ala-Pro-Pro-Glu-Lys-Ile-Ala-Ile-Val-Gly-Ala-Gly-Ile.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: January 5, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Vincent E. Groppi, Jr., Martin R. Deibel, Jr., Mark L. Wolfe, Anthony W. Yem